Filter Results:
(2,525)
Show Results For
- All HBS Web
(5,300)
- People (16)
- News (1,939)
- Research (2,525)
- Events (3)
- Multimedia (214)
- Faculty Publications (1,884)
Show Results For
- All HBS Web
(5,300)
- People (16)
- News (1,939)
- Research (2,525)
- Events (3)
- Multimedia (214)
- Faculty Publications (1,884)
Sort by
- 09 May 2018
- Research & Ideas
A Simple Way for Restaurant Inspectors to Improve Food Safety
new research about how scheduling affects worker behavior. The potential result: Americans could avoid 19 million foodborne illnesses, nearly 51,000 hospitalizations, and billions of dollars of related medical costs. Government health... View Details
- January 2013 (Revised February 2013)
- Supplement
Shouldice Hospital Limited (B)
By: James Heskett and Roger Hallowell
Heskett, James, and Roger Hallowell. "Shouldice Hospital Limited (B)." Harvard Business School Supplement 913-405, January 2013. (Revised February 2013.)
- Article
Biosimilars and Follow-On Products in the United States: Adoption, Prices, and Users
By: Ariel Dora Stern, Jacqueline L. Chen, Melissa Ouellet, Mark R. Trusheim, Zeid El-Kilani, Amber Jessup and Ernst R. Berndt
Biologic drugs account for a disproportionate share of the increase in pharmaceutical spending in the U.S. and worldwide. Against this backdrop, many look to the expanding market for biosimilars—follow-on products to biologic drugs—as a vehicle for controlling... View Details
Keywords: Pharmaceuticals; Drug Spending; Drug Pricing; Health Care and Treatment; Spending; Price; Markets; Cost Management; United States
Stern, Ariel Dora, Jacqueline L. Chen, Melissa Ouellet, Mark R. Trusheim, Zeid El-Kilani, Amber Jessup, and Ernst R. Berndt. "Biosimilars and Follow-On Products in the United States: Adoption, Prices, and Users." Health Affairs 40, no. 6 (June 2021): 989–999.
- June 2019
- Teaching Note
Zebra Medical Vision
By: Shane Greenstein and Sarah Gulick
Teaching note is meant to accompany Zebra Medical Vision case, which offers a look at a company’s decisions as a small startup competing with other startups and major technology companies. It also demonstrates the challenges faced by a machine learning company working... View Details
- March 17, 2017
- Article
How Economics Can Shape Precision Medicines
By: Ariel Dora Stern, Brian M. Alexander and Amitabh Chandra
Many public and private efforts in coming years will focus on research in precision medicine, developing biomarkers to indicate which patients are likely to benefit from a certain treatment so that others can be spared the cost—financial and physical—of being treated... View Details
Stern, Ariel Dora, Brian M. Alexander, and Amitabh Chandra. "How Economics Can Shape Precision Medicines." Science 355, no. 6330 (March 17, 2017): 1131–1133.
- 25 Oct 2016
- First Look
October 25, 2016
Bonitas to innovate, grow, and compete with market leader Discovery as well as providers of alternative insurance products. Bonitas must also plan ahead for the rollout of national health insurance—a deeply politicized issue in a country... View Details
Keywords: Sean Silverthorne
- June 2024
- Supplement
Legacy Partners (B)
By: Richard S. Ruback and Royce Yudkoff
Pre-abstract: Instructors should consider the timing of making videos available to students, as they may reveal key case details.
Abstract: Stephen Holbrook and Austin Pulsipher (both HBS '19) had been leading Nutrishare since acquiring the company six... View Details
Abstract: Stephen Holbrook and Austin Pulsipher (both HBS '19) had been leading Nutrishare since acquiring the company six... View Details
Keywords: Acquisition; Small Business; Cost vs Benefits; Decisions; Business Education; Corporate Entrepreneurship; Leadership Style; Leading Change; Business or Company Management; Problems and Challenges; Health Care and Treatment; Health Disorders; Medical Specialties; Nutrition; Supply Chain Management; Growth Management; Health Industry; Health Industry; United States; California
Ruback, Richard S., and Royce Yudkoff. "Legacy Partners (B)." Harvard Business School Multimedia/Video Supplement 224-726, June 2024.
- June 2000
- Case
Lifeline Systems, Inc. (A)
By: H. Kent Bowen and Marilyn Matis
Lifeline Systems provides emergency response equipment to the elderly who live at home. The company uses local hospitals to market, sell, and install these units in homes, while the hospital monitors and calls for aid to respond to emergency calls from the elderly... View Details
Keywords: Health Care and Treatment; Product Marketing; Sales; Problems and Challenges; Growth and Development Strategy; Managerial Roles; Service Operations; Information Infrastructure; Age; Service Delivery; Restructuring; Crisis Management; Health Industry; Health Industry
Bowen, H. Kent, and Marilyn Matis. "Lifeline Systems, Inc. (A)." Harvard Business School Case 600-099, June 2000.
- July 2019
- Article
The Impact of Price Regulation on the Availability of New Drugs in Germany
By: Ariel Dora Stern, Felicitas Pietrulla, Annika Herr, Aaron S. Kesselheim and Ameet Sarpatwari
The 2011 German Pharmaceutical Market Restructuring Act (“AMNOG”) subjected branded, non-rare disease drugs to price regulation based on an assessment of their clinical benefit. Assessment outcomes range from “major added benefit” to “less benefit than the appropriate... View Details
Keywords: Regulation; Pharmaceuticals; Healthcare; Health Care and Treatment; Price; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; Germany
Stern, Ariel Dora, Felicitas Pietrulla, Annika Herr, Aaron S. Kesselheim, and Ameet Sarpatwari. "The Impact of Price Regulation on the Availability of New Drugs in Germany." Health Affairs 38, no. 7 (July 2019): 1182–1187.
- January–February 2021
- Article
Food and Drug Administration Guidance Documents and New Medical Devices: The Case of Breast Prostheses
By: Rachel E. Weitzman, Ariel Dora Stern and Daniel B. Kramer
As pressure mounts on the Food and Drug Administration (FDA) to speed its review process for novel devices, and budgetary pressures further strain its resources, the critical role of guidance documents in assuring consistent, rigorous, and scientifically grounded... View Details
Keywords: Medical Devices; FDA; Health Care and Treatment; Government Administration; Information; Standards
Weitzman, Rachel E., Ariel Dora Stern, and Daniel B. Kramer. "Food and Drug Administration Guidance Documents and New Medical Devices: The Case of Breast Prostheses." American Journal of Therapeutics 28, no. 1 (January–February 2021).
- October 1998 (Revised April 2000)
- Background Note
Complexity and Error in Medicine
By: Richard M.J. Bohmer
Reviews the issues underlying the rate of error in medical practice and discusses the range of potential management interventions to decrease the risk of error. View Details
Keywords: Health Care and Treatment; Management Practices and Processes; Risk and Uncertainty; Complexity
Bohmer, Richard M.J. "Complexity and Error in Medicine." Harvard Business School Background Note 699-024, October 1998. (Revised April 2000.)
- 14 Jun 2016
- First Look
June 14, 2016
challenging work environments. This article focuses on two such contexts—health care and education. The authors theorize differences in psychological safety based on work type, hierarchical status, and leadership effectiveness. Consistent... View Details
Keywords: Sean Silverthorne
- Article
Treatment Of Opioid Use Disorder Among Commercially Insured U.S. Adults, 2008–17
By: Karen Shen, Eric Barrette and Leemore S. Dafny
There is abundant literature on efforts to reduce opioid prescriptions and misuse, but comparatively little on the treatment provided to people with opioid use disorder (OUD). Using claims data representing 12–15 million nonelderly adults covered through commercial... View Details
Keywords: Opioid Treatment; Medication-assisted Treatment; Substance Use Disorder; Private Insurance; Health Disorders; Health Care and Treatment; Insurance; United States
Shen, Karen, Eric Barrette, and Leemore S. Dafny. "Treatment Of Opioid Use Disorder Among Commercially Insured U.S. Adults, 2008–17." Health Affairs 39, no. 6 (June 2020): 993–1001.
- April 1998
- Case
Cephalon, Inc.
By: Peter Tufano
In early 1997, Cephalon, awaited an FDA panel's decision on whether its drug, Myotrophin, would be approved. If the drug was approved, the firm might need substantial additional funds to commercialize as well as to buy back rights to it (which had been sold earlier to... View Details
Keywords: Risk Management; Financing and Loans; Health Care and Treatment; Pharmaceutical Industry; United States
Tufano, Peter, Geoffrey Verter, and Markus Mullarkey. "Cephalon, Inc." Harvard Business School Case 298-116, April 1998.
- 2023
- Working Paper
The Political Economy of a 'Miracle Cure': The Case of Nebulized Ibuprofen and Its Diffusion in Argentina
By: Sebastian Calónico, Rafael Di Tella and Juan Cruz Lopez Del Valle
We document the diffusion of nebulized ibuprofen in Argentina as a treatment for COVID-19. As the pandemic spread, this clinically unsupported drug reached thousands of patients, even some seriously ill, despite warnings by the regulator and medical societies. Detailed... View Details
Keywords: COVID-19; Health Care and Treatment; Health Pandemics; Adoption; Behavior; Governing Rules, Regulations, and Reforms; Learning
Calónico, Sebastian, Rafael Di Tella, and Juan Cruz Lopez Del Valle. "The Political Economy of a 'Miracle Cure': The Case of Nebulized Ibuprofen and Its Diffusion in Argentina." NBER Working Paper Series, No. 31781, October 2023.
- Article
Value of New Performance Information in Healthcare: Evidence from Japan
By: Susanna Gallani, Takehisa Kajiwara and Ranjani Krishnan
Mandatory measurement and disclosure of outcome measures are commonly used policy tools in
healthcare. The effectiveness of such disclosures relies on the extent to which the new information produced by the mandatory system is internalized by the healthcare... View Details
Keywords: Value Of Information; Feedback; Patient Satisfaction; Healthcare; Health Care and Treatment; Satisfaction; Information; Measurement and Metrics; Performance Improvement
Gallani, Susanna, Takehisa Kajiwara, and Ranjani Krishnan. "Value of New Performance Information in Healthcare: Evidence from Japan." International Journal of Health Economics and Management 20, no. 4 (December 2020): 319–357.
- 02 Sep 2002
- What Do You Think?
What Can Business Schools Do to Avoid Bad Apples?
Summing Up This month's column resulted in a number of suggestions for sorting out the "bad apples" among applicants to MBA programs across the country. But just as many respondents questioned the underlying assumptions of the column. Many respondents... View Details
Keywords: by James Heskett
- January 2018
- Article
Innovation Incentives and Biomarkers
By: Ariel Dora Stern, Brian M. Alexander and Amitabh Chandra
Previously, we have discussed the importance of economic incentives in shaping markets for precision medicines. Here we consider incentives for biomarker development, including discovery and establishment. Biomarkers can reveal valuable information regarding diagnosis... View Details
Stern, Ariel Dora, Brian M. Alexander, and Amitabh Chandra. "Innovation Incentives and Biomarkers." Clinical Pharmacology & Therapeutics 103, no. 1 (January 2018): 34–36.
- May 2011
- Article
Nonsimultaneous Chains and Dominos in Kidney Paired Donation—Revisited
By: Itai Ashlagi, Duncan S. Gilchrist, Alvin E. Roth and Michael A. Rees
Since 2008 kidney exchange in America has grown in part from the incorporation of non-directed donors in transplant chains rather than simple exchanges. It is controversial whether these chains should be performed simultaneously ("domino paired donation," DPD) or... View Details
Keywords: ABO Incompatibility; Allosensitization; Paired Kidney Exchange; Regional Sharing; Simulation Models; Transplantation Policy; Health Care and Treatment; Supply Chain; Risk and Uncertainty; Logistics; United States
Ashlagi, Itai, Duncan S. Gilchrist, Alvin E. Roth, and Michael A. Rees. "Nonsimultaneous Chains and Dominos in Kidney Paired Donation—Revisited." American Journal of Transplantation 11, no. 5 (May 2011): 984–994.
- 02 Mar 2010
- First Look
First Look: March 2
bonus payments based upon provider reporting and performance on a set of quality measures. This case allows readers to examine health care provider strategy, development and... View Details
Keywords: Martha Lagace